SAN DIEGO--(BUSINESS WIRE)--Optimer Pharmaceuticals, Inc. (Nasdaq:OPTR) today announced its financial results for the third quarter ended September 30, 2008. Optimer reported a net loss for the third quarter of 2008 of $9.2 million, or $0.31 per share, compared to a net loss of $6.5 million, or $0.28 per share, for the same period in 2007. Research and development expenses in the third quarter of 2008 were $7.9 million compared to $5.5 million in the third quarter of 2007. The increase was primarily due to expenses related to OPT-80 and Prulifloxacin Phase 3 clinical trials.
